136 related articles for article (PubMed ID: 28830801)
1. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis.
Hammons L; Brazauskas R; Pasquini M; Hamadani M; Hari P; D'Souza A
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):105-111. PubMed ID: 28830801
[TBL] [Abstract][Full Text] [Related]
2. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
[TBL] [Abstract][Full Text] [Related]
5. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.
Warsame R; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Leung N; Dingli D; Lust JA; Ketterling RP; Lin Y; Russell S; Hwa L; Kapoor P; Go RS; Zeldenrust SR; Kyle RA; Rajkumar SV; Dispenzieri A
Blood Cancer J; 2015 May; 5(5):e310. PubMed ID: 25933374
[TBL] [Abstract][Full Text] [Related]
6. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
7. AL amyloidosis with a localized B cell neoplasia.
Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.
Zanwar S; Gertz MA; Muchtar E
J Natl Compr Canc Netw; 2023 Jan; 21(1):83-90. PubMed ID: 36630897
[TBL] [Abstract][Full Text] [Related]
9. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
Granzow M; Hegenbart U; Hinderhofer K; Hose D; Seckinger A; Bochtler T; Hemminki K; Goldschmidt H; Schönland SO; Jauch A
Haematologica; 2017 Jul; 102(7):1281-1290. PubMed ID: 28341732
[TBL] [Abstract][Full Text] [Related]
10. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
12. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
13. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance.
Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS
Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.
Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz M
Haematologica; 2018 Jul; 103(7):1229-1234. PubMed ID: 29674497
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous light chain amyloidosis with multiple myeloma: A concise review.
Andrei M; Wang JC
Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):71-81. PubMed ID: 30261180
[TBL] [Abstract][Full Text] [Related]
17. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
Bryce AH; Ketterling RP; Gertz MA; Lacy M; Knudson RA; Zeldenrust S; Kumar S; Hayman S; Buadi F; Kyle RA; Greipp PR; Lust JA; Russell S; Rajkumar SV; Fonseca R; Dispenzieri A
Haematologica; 2009 Mar; 94(3):380-6. PubMed ID: 19211640
[TBL] [Abstract][Full Text] [Related]
18. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
Hu Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
[TBL] [Abstract][Full Text] [Related]
19. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence in situ hybridisation combined with CD138 immunomagnetic sorting is effective to identify cytogenetic abnormalities which play significant prognostic roles in Chinese AL amyloidosis patients.
Liu Y; Lai Y; Ma L; Wen L; Duan W; Wang F; Kang Y; Chen H; Chen Y; Gao L; Huang X; Lu J
Amyloid; 2020 Sep; 27(3):208-209. PubMed ID: 32024388
[No Abstract] [Full Text] [Related]
[Next] [New Search]
